Redwood City, CA (PRWEB) August 05, 2014
Neural ID, the provider of the only enterprise biosignal analytics platform spanning the pharmaceutical lifecycle, today announced that Neural ID’s Intelligent Waveform Service (IWS) will be compatible with the TIBCO Spotfire® platform, thereby enabling PerkinElmer’s TIBCO Spotfire® platform users to interact directly with biosignal traces across Discovery and Preclinical R&D phases (GLP).
“Neural ID’s IWS expert-driven machine learning templates enable a whole new user experience, driving down cost and reducing time to analysis by a factor of ten with our pharmaceutical customers. The Neural ID IWS platform offers new interactive tools and a scalable pattern based approach that is resonating from the bench to the BI analyst,” said Tim Carruthers, CEO of Neural ID. “Neural ID has built a reputation among researchers by enabling them to interact with individual biosignals, helping researchers make better decisions faster.”
“The volume and diversity of data that scientists need to capture and analyze to make knowledgeable and informed decisions is an immense challenge. A researcher’s ability to process vast amounts of complex data from a multitude of sources affects their ability to positively impact both research and business intelligence efforts,” said, Karen Madden, President of Informatics at PerkinElmer. “The addition of this interoperability between the TIBCO Spotfire® platform and Neural ID’s IWS platform capabilities will enable our TIBCO Spotfire® platform customers to leverage an enterprise-class biosignal analytics platform to address scientists’ data processing challenges.”
Neural ID's IWS platform leverages human expertise via machine learning to automate biosignal recognition and analysis from multiple instrument platforms, improving drug research and development by addressing the critical issues of risk management, cost con
Copyright©2014 Vocus, Inc.
All rights reserved